Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up
Open Access
- 1 September 2020
- journal article
- research article
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 39 (3), 334-343
- https://doi.org/10.23876/j.krcp.20.015
Abstract
Background: Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have been previously treated with ferric gluconate (FX). Markers of iron metabolism, erythropoietin (EPO) doses, and effects on anemic status have been analysed. Methods: The study was performed with a follow up period of 4 years, when patients were treated before with FX and then switched to FCM. A total of 25 patients were included in the study. Results: FCM increased transferrin saturation (TSAT) levels by 11.9% (P < 0.001) with respect to FX. Events of TSAT less than 20% were reduced during FCM. The monthly dose of EPO was reduced in the FCM period (-6,404.1 international unit [IU]; 95% confidence interval, -10,643.5 IU; -2,164.6 IU; P = 0.003), as well as the erythropoietin resistance index (P = 0.004). During the period with FCM, ferritin levels were higher than during FX (P < 0.001), while transferrin was reduced (P = 0.001). Conclusion: During FCM treatment, minor doses of EPO were administered if compared to those delivered during FX therapy. Stable and on target levels of hemoglobin were maintained with better control of anemia through high levels of ferritin and TSAT.This publication has 24 references indexed in Scilit:
- Pharmacokinetics of ferric bepectate—a new intravenous iron drug for treating iron deficiencyBasic & Clinical Pharmacology & Toxicology, 2019
- Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directionsClinical Kidney Journal, 2017
- Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trialNephrology Dialysis Transplantation, 2013
- Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center studyNephrology Dialysis Transplantation, 2012
- A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patientsNephrology Dialysis Transplantation, 2010
- The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical studyNephrology Dialysis Transplantation, 2010
- Ferric CarboxymaltoseDrugs, 2009
- The Role of Hepcidin in Iron Homeostasis and Anemia in Hemodialysis PatientsSeminars in Dialysis, 2009
- Structure, chemistry, and pharmacokinetics of intravenous iron agents.Published by Rockefeller University Press ,2004
- Single‐Dose Pharmacokinetics of Sodium Ferric Gluconate Complex in Iron‐Deficient SubjectsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004